CA3230295A1 - Method of treatment - Google Patents

Method of treatment Download PDF

Info

Publication number
CA3230295A1
CA3230295A1 CA3230295A CA3230295A CA3230295A1 CA 3230295 A1 CA3230295 A1 CA 3230295A1 CA 3230295 A CA3230295 A CA 3230295A CA 3230295 A CA3230295 A CA 3230295A CA 3230295 A1 CA3230295 A1 CA 3230295A1
Authority
CA
Canada
Prior art keywords
seq
dna
disease
binding protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3230295A
Other languages
English (en)
French (fr)
Inventor
James A. Campbell
Valentina DUBLJEVIC
James E. Hansen
Xiaoyong Chen
Benedette J. CUFFARI
Anupama Shirali
Jiangbing Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nucleus Therapeutics Pty Ltd
Yale University
Original Assignee
Nucleus Therapeutics Pty Ltd
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nucleus Therapeutics Pty Ltd, Yale University filed Critical Nucleus Therapeutics Pty Ltd
Publication of CA3230295A1 publication Critical patent/CA3230295A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3230295A 2021-08-30 2022-08-30 Method of treatment Pending CA3230295A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163238657P 2021-08-30 2021-08-30
US63/238,657 2021-08-30
US202263324784P 2022-03-29 2022-03-29
US63/324,784 2022-03-29
PCT/US2022/075639 WO2023034778A1 (en) 2021-08-30 2022-08-30 Method of treatment

Publications (1)

Publication Number Publication Date
CA3230295A1 true CA3230295A1 (en) 2023-03-09

Family

ID=85411616

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3230295A Pending CA3230295A1 (en) 2021-08-30 2022-08-30 Method of treatment

Country Status (6)

Country Link
US (1) US20250188194A1 (https=)
EP (1) EP4396225A4 (https=)
JP (1) JP2024530990A (https=)
AU (1) AU2022337199A1 (https=)
CA (1) CA3230295A1 (https=)
WO (1) WO2023034778A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025129254A1 (en) * 2023-12-19 2025-06-26 Nucleus Therapeutics Pty Ltd Composition comprising a cell penetrating, anti-dna binding protein and methods of treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6178785B2 (ja) * 2011-04-01 2017-08-09 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 細胞浸透性抗ｄｎａ抗体およびｄｎａ修復を阻害するためのその使用
EP3471777A1 (en) * 2016-06-15 2019-04-24 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
US20210340279A1 (en) * 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
WO2021077070A1 (en) * 2019-10-18 2021-04-22 Yale University Compositions and methods for inhibition of cell-penetrating antibodies

Also Published As

Publication number Publication date
EP4396225A4 (en) 2025-07-02
WO2023034778A1 (en) 2023-03-09
US20250188194A1 (en) 2025-06-12
AU2022337199A1 (en) 2024-03-21
EP4396225A1 (en) 2024-07-10
JP2024530990A (ja) 2024-08-27

Similar Documents

Publication Publication Date Title
US10322174B2 (en) Neutralizing anti-TL1A monoclonal antibodies
WO2019238012A1 (zh) 可以阻断CD47和SIRPa相互作用的抗体及其应用
WO2020143710A1 (zh) 一种抗cd73单克隆抗体及其应用
RU2744909C2 (ru) Способ лечения или предотвращения инсульта
JP2020188765A (ja) Ｌｏｘ１特異的結合タンパク質及びその使用
WO2012176765A1 (ja) 抗ヒトｐ－カドへリン（ｃｄｈ３）遺伝子組み換え抗体
JP2019514875A (ja) 肝病態を治療又は予防する方法
EP3495390A1 (en) Novel antibody against programmed cell death protein (pd-1), and use thereof
JP2021533770A (ja) 抗ＩＬ−１β抗体およびその医薬組成物およびそれらの使用
EP2048162A1 (en) Novel monoclonal antibody and use of the same
US20190092848A1 (en) Methods of treating bone diseases, disorders and/or injuries and reagents therefor
US20250188194A1 (en) Method of treatment
CN102333543B (zh) 细胞粘附抑制剂及其用途
JP6029019B2 (ja) 細胞接着阻害剤、細胞増殖阻害剤、並びに癌の検査方法および検査用キット
US11028184B2 (en) Long-acting PCSK9-specific binding protein and application thereof
US8722041B2 (en) Anti-human equilibrative nucleoside transporter 1 (hENT1) antibodies and methods of use thereof
JP7458049B2 (ja) 自己免疫疾患治療剤
JPWO2006093337A1 (ja) 癌の予防・治療剤
US20250340670A1 (en) Antibody specifically binding to ptk7 and use thereof
CN118201958A (zh) 治疗方法
JP2022547018A (ja) 抗ｃｘｃｒ２抗体およびその使用
WO2024153193A1 (en) Bi-specific molecules targeting sirpa and claudin 18.2
JP7453694B2 (ja) 細胞外膜に露出されるリシル－ｔＲＮＡ合成酵素のＮ－末端領域に特異的に結合する抗体
HK1242603B (en) Method of treating or preventing stroke

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240726

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250722

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250722